ArticleGastrointestinal endoscopy2020
Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.
Article in Gastrointestinal endoscopy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- [Endoscopic diagnostics and treatment of early neoplasia of the esophagus].Chirurgie (Heidelberg, Germany) · 2026Review
- A prospective cohort study evaluating disease-specific mortality in patients with early-stage Barrett's esophagus-related neoplasia following endoscopic therapy.Surgical endoscopy · 2026Article
- Expanded Indications in Advanced Endoscopic Resection of Malignant Gastrointestinal Lesions.Current gastroenterology reports · 2026Review
- Therapeutic outcomes of different treatment approaches for T1a-M3/T1b esophageal cancer and development of a prognostic prediction model.NPJ digital medicine · 2025Article
- Modification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10-Year Experience.Cancer reports (Hoboken, N.J.) · 2025Article
- Risk factors associated with poor prognosis after endoscopic treatment of clinical T1a esophageal cancer.Surgical endoscopy · 2025Article
- Outcomes after radical endoscopic resection of high risk T1 esophageal adenocarcinoma: an international multicenter retrospective cohort study.Endoscopy · 2025Article
- Current status and perspectives of esophageal cancer: a comprehensive review.Cancer communications (London, England) · 2025Review
- Review
- From endoscopy to surgery: a translational perspective on early esophageal cancer management.Frontiers in medicine · 2025Article
- Outcomes for endoscopic submucosal dissection of pathologically staged T1b esophageal cancer: a multicenter study.Gastrointestinal endoscopy · 2022Article
- Long-term outcomes of endoscopic mucosal resection for early-stage esophageal adenocarcinoma.Surgical endoscopy · 2022Article
- Endoscopic Management of Barrett's Esophagus.Digestive diseases and sciences · 2022Review
- Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.World journal of gastrointestinal oncology · 2022Review
- State-of-the-art management of dysplastic Barrett's esophagus.Gastroenterology report · 2022Review
- Clinical and pathological predictors of failure of endoscopic therapy for Barrett's related high-grade dysplasia and early esophageal adenocarcinoma.Surgical endoscopy · 2021Article
- The role of surgery type in postoperative atrial fibrillation and in-hospital mortality in esophageal cancer patients with preserved left ventricular ejection fraction.World journal of surgical oncology · 2020Article
Corrections and comments
Authors and funding
20 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsThe treatment of submucosal (T1b) esophageal adenocarcinoma (EAC) remains in evolution, with some evidence supporting endoscopic management of low-risk lesions. Using a multicenter cohort, we evaluated outcomes of patients with T1b EAC and predictors of survival.
methodsPatients diagnosed between 2001 and 2016 with T1b EAC were identified from 3 academic medical centers in the United States. Demographic, clinical, and outcome data were collected. Outcomes studied were overall and cancer-free survival. Cox proportional hazards models were constructed to assess independent predictors of survival.
resultsOne hundred forty-one patients were included, of whom 68 (48%) underwent esophagectomy and 73 (52%) were treated endoscopically. Most patients (85.8%) had high-risk histologic features. Thirty-day operative mortality was 2.9%. Median follow-up in the esophagectomy and endoscopic cohorts was 49.4 and 43.4 months, respectively. Patients treated endoscopically were older with higher comorbidity scores, with 46 (63%) achieving histologic remission. Nineteen patients (26.0%) also received chemoradiation. Five-year overall survival rates in the surgical and endoscopic cohorts were 89% and 59%, respectively, whereas 5-year cancer-free survival rates were 92% and 69%. Presence of high-risk histologic features was associated with reduced overall survival.
conclusionsIn this large multicenter study of patients with T1b EAC, esophagectomy was associated with improved overall but not cancer-free survival. High-risk histologic features were associated with poorer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.